Pavan Kumar Prathipati
Overview
Explore the profile of Pavan Kumar Prathipati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattarai P, Hegde P, Li W, Prathipati P, Stevens C, Yang L, et al.
J Med Chem
. 2022 Dec;
66(1):170-187.
PMID: 36563291
Tuberculosis (TB), caused by (), is one of the leading causes of death in developing countries. Non-tuberculous mycobacteria (NTM) infections are rising and prey upon patients with structural lung diseases...
2.
Mandal S, Sunagawa S, Prathipati P, Belshan M, Shibata A, Destache C
Nanomaterials (Basel)
. 2022 Jun;
12(11).
PMID: 35683795
The C-C motif chemokine receptor-5 (CCR5) expression on the T-cell surface is the prime barrier to HIV/AIDS eradication, as it promotes both active human immunodeficiency virus (HIV)-infection and latency; however,...
3.
Mandal S, Prathipati P, Sunagawa S, Destache C
Antimicrob Agents Chemother
. 2021 Feb;
65(4).
PMID: 33526487
The antiretroviral treatment (ART) approach is the best-prescribed approach to date for preexposure prophylaxis (PrEP) for high-risk individuals. However, the daily combination antiretroviral (cARV) regimen has become cumbersome for healthy...
4.
Jadhav G, Prathipati P, Chauhan H
Expert Opin Drug Discov
. 2020 Apr;
15(7):739-743.
PMID: 32228102
No abstract available.
5.
Prathipati P, Mandal S, Pon G, Vivekanandan R, Destache C
Pharm Res
. 2019 May;
36(7):108.
PMID: 31111294
There are errors in the published article (Volume 34, Number 12, pp. 2749-2755). The errors occurred in pharmacokinetic study design of materials and methods section on page 2750-51.
6.
Mandal S, Kang G, Prathipati P, Zhou Y, Fan W, Li Q, et al.
J Control Release
. 2019 May;
304:101.
PMID: 31082646
No abstract available.
7.
Mandal S, Prathipati P, Belshan M, Destache C
Antiviral Res
. 2019 Apr;
167:83-88.
PMID: 30991088
Bictegravir (BIC), a newly FDA-approved integrase strand transfer inhibitor (INSTI), as a single tablet regimen has proven efficacious in treating HIV-1 and SIV viruses, with reduced resistance. BIC clinical trials...
8.
Prathipati P, Mandal S, Destache C
Ther Deliv
. 2019 Feb;
10(2):107-112.
PMID: 30729884
HIV is one of the most devastating viral infections the world has ever encountered. Ever since HIV was first identified in the 1980s, it has claimed millions of lives worldwide....
9.
Mandal S, Kang G, Prathipati P, Zhou Y, Fan W, Li Q, et al.
J Control Release
. 2018 Dec;
294:216-225.
PMID: 30576746
Daily oral antiretroviral (ARV) drugs for pre-exposure prophylaxis (PrEP) has proven efficacy for diverse groups of high-risk individuals. However, daily dosing regimen has augmented non-adherence. These experiments comparatively investigated the...
10.
Mandal S, Khandalavala K, Pham R, Bruck P, Varghese M, Kochvar A, et al.
Polymers (Basel)
. 2018 Nov;
9(9).
PMID: 30450244
To adequately reduce new HIV infections, development of highly effective pre-exposure prophylaxis (PrEP) against HIV infection in women is necessary. Cellulose acetate phthalate (CAP) is a pH sensitive polymer with...